Priverzhennost' k ingalyatsionnoyterapii i kontrol' bronkhial'noy astmy



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

В данной статье рассматриваются особенности применения комбинированной терапии салметеролом и
флутиказона пропионатом (Серетид) с учетом основных характеристик используемых для их доставки
ингаляционных устройств, обсуждаются различия в показателях осаждения лекарственной субстанции
в легких, потенциальные преимущества и недостатки различных устройств и другие факторы, которые
необходимо учитывать при выборе ингалятора, соответствующего индивидуальным потребностям
пациента, для повышения его приверженности к долговременной терапии.

References

  1. Global Initiative for asthma. Global strategy for asthma management and prevention. Update 2009/-www.ginasthma.org
  2. Чучалин А.Г., Белевский А.С., Огородова Л.М., Петровский Ф.И., Куликов Е.С. Эффективность стратегий достижения и поддержания контроля над бронхиальной астмой в условиях реальной клинической практики: данные многоцентрового исследования СТРЕЛА-АСТ. Пульмонология. 2010, № 1, с. 80-86.
  3. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика» (третье изд.,тспр.и доп. Издательский дом «Атмосфера». М., 2008,108 с.
  4. Sabate E. WHO Adherence Meeting Report. Geneva,World Health Organization, 2001.
  5. Haynes R.B. Determinants of compliance: The disease and the mechanics of treatment. Baltimore, Johns Hopkins University Press, 1979.
  6. Haynes RB. Interventions for helping patients to follow prescriptions for medications. Cochrane Database of Systematic Reviews. 2001.
  7. Бушуева Н.А., Сенкевич Н.Ю., Белевский А.С., Чучалин А.Г. Сравнительный анализ факторов кооперативности больных бронхиальной астмой. Пульмонология. 2000, № 3, с. 53-61.
  8. Овчаренко С.И., Акулова М.Н., Смулевич А.Б. Что может улучшить контроль течения бронхиальной астмы. Сonsilium Medicum. 2010, № 3, т. 12.
  9. Овчаренко С.И., Акулова М.Н. Оценка применения комбинированного ингаляционного препарата в терапии больных бронхиальной астмой с учетом длительности заболевания. Терапевтический архив. 2009, № 3.
  10. ОгородоваЛ.М., ПетровскийФ.И., ДеевИ.А Средства ингаляционной доставки препаратов: взгляд врача и взгляд пациента. Новые лекарства и новости фармакотерапии. 2002, № 2, с. 33-36.
  11. Bender B.G., Bender S.E. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol. Allergy Clin. North Am. 2005, v. 25, p. 107-130.
  12. Milgrom H., Wamboldt F., Bender B. Monitoring adherence to the therapy of asthma. Curr. Opin. Allergy Clin. Immunol. 2002, v. 2, p. 201-205.
  13. Lasmar L., Camargos P., Champs N.S. et al. Adherence rate to inhaled corticosteroids and their impact on asthma control Allergy. 2009, v. 64 (5), p. 784-789.
  14. Авдеев С.Н. Бронхиальная астма в таблицах и схемах. «Атмосфера». М., 2005, 47 с.
  15. Авдеев С.Н. Бронхиальная астма в таблицах и схемах. «Атмосфера». М., 2005, 47 с.
  16. Авдеев С. Н .Устройства доставки ингаляционных препаратов, используемых при терапии заболеваний дыха- тельных путей. Рус. Мед. Журн. 2002, № 5, т. 10.
  17. Borgström L., Clark A., Olsson B. Introduction. 1000 years of pharmaceutical aerosols: what remains to be done? J. Aerosol Med. Pulm. Drug. Deliv. 2010, v. 23 Suppl 2, p. 1-4.
  18. The Montreal Protocol on Substances that Deplete the Ozone Layer as adjusted and/or amended in London 1990, Copenhagen 1992, Vienna 1995, Montreal 1997, Beijing 1999. Published 2000.
  19. Nair A., Clearie K., Menzies D. et al. A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Pulm. Pharmacol. Ther. 2009, v. 22 (4), p. 305-310.
  20. Longest P.W., Hindle M. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. J. Aerosol. Med. Pulm. Drug. Deliv. 2009, v. 22 (3), p. 271-283.
  21. Toogood J.H., White F.A., Baskerville J.C. et al. Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J. Allergy Clin. Immunol. 1997, v. 99, p. 186-193.
  22. Magnussen H. Novolizer: how does it fit into inhalation therapy? Curr. Med. Res. Opin. 2005, v. 21 Suppl 4, p. 39-46; discussion S47.
  23. Chrystyn H. The DiskusTM: a review of its position among dry powder inhaler devices .Int. J. ournal of Clin. Pract. 2007, v. 61, Issue 6, p. 1022-1036.
  24. Atkins P.J. Dry powder inhalers: an overview. Respir. Care. 2005, v. 50 (10), p. 1304-1312.
  25. Melani A.S.Inhalatory therapy training: a priority challenge for the physician. Acta Biomed. 2007, v. 78 (3), p. 233-245.
  26. Brocklebank D., Ram F., Wright J. et al.Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol. Assess. 2001, v. 5 (26), p. 1-149.
  27. Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23 (5), p. 323-328.
  28. Molimard M., Raherison C., Lignot S. et al. Moore Assessment of Handling of Inhaler Devices in Real Life:An Observational Study in 3811 Patients in Primary Care J. of Aerosol Medicine. 2003, v. 16, No. 3, p. 249-254.
  29. Daley-Yates P.T., Parkins D.A., Thomas M.J. et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. Clin. Ther. 2009, v. 31 (2), p. 370-385.
  30. Thorsson L., Edsbacker S., Kallen A. Lofdahl C.G. Pharmacokinetics and systemic activity of Fluticasone via Diskus1 and pMDI, and of budesonide via Turbuhaler1 Br. J. Clin. Pharmacol. 2001, v. 52, p. 529-538.
  31. Byron P.R., Hindle M., Lange C.F., Longest P.W., McRobbie D., Oldham M.J., Olsson B., Thiel C.G., Wachtel H., Finlay W.H. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23 Suppl 2, p. 59-69.
  32. Rostami A.A.Computational modeling of aerosol deposition in respiratory tract: a review. Inhal. Toxicol. 2009, v. 21 (4), p. 262-290.
  33. Scheuch G., Bennett W., Borgström L. et al. Deposition, imaging, and clearance: what remains to be done? J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23 Suppl 2, p. 39-57.
  34. Fleming J., Conway J., Majoral C. et al. The Use of Combined Single Photon Emission Computed Tomography and X-ray Computed Tomography to Assess the Fate of Inhaled Aerosol. J. Aerosol. Med. Pulm. Drug. Deliv. 2010, Dec 18.
  35. Inthavong K., Choi L.T., Tu J., Ding S., Thien F. Micron particle deposition in a tracheobronchial airway model under different breathing conditions. Med. Eng. Phys. 2010, v. 32 (10), p. 1198-1212.
  36. Hein S., Bur M., Schaefer U.F., Lehr C.M. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. Eur. J. Pharm. Biopharm. 2011, v. 77 (1), p. 132-128.
  37. Hein S., Bur M., Kolb T. et al.The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) in vitro system: design and experimental protocol. Altern. Lab. Anim. 2010, v. 38 (4), p. 285-295.
  38. Tarsin W.Y., Pearson S.B., Assi K.H., Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int. J. Pharm. 2006, v. 316, p. 131-137.
  39. Burnell P.K., Small T., Doig S. et al. Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir. Med. 2001, v. 95 (5), p. 324-330.
  40. Kokot M. Selection of a personal dry powder inhaler based on peak inspiratory flow measurements in selected groups of patients with bronchial obstruction. Pol. Merkur. Lekarski. 2000, v. 9, p. 672-676.
  41. Bisgaard H., Klug B., Sumby B.S., P.K.P. Burnell Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 1998, v. 11, p. 1111-1115.
  42. Bracamonte T., Schauer U., Emeryk A. et al. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the DiskusTM or pressurised metered dose inhaler in children with asthma. Clin. Drug. Invest. 2005, v. 25, p. 1-11.
  43. Ashurst I.C., Prime D., Haywood P.A. Development of a dry powder inhaler device containing a combination of salmeterol and fluticasone propionate. Eur. Respir. J. 1998, v. 12 (Suppl. 28), p. 93.
  44. Busse W.W., Shah S.R., Somerville L. et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/ salmeterol dry powder inhaler in asthma patients. J. Allergy Clin. Immunol. 2008, v. 121 (6), p. 1407-1414.
  45. Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J. Asthma. 2005, v. 42 (9), p. 715-724.
  46. Johansson G., McIvor R.A., D'Ambrosio F.P. et al. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma. Clin. Drug. Investig. 2001, v. 21 (9), p. 633.
  47. Van den Berg N.J., Ossip M.S., Hederos C.A. et al. Salmeterol/ fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol. 2000, v. 30 (2), p. 97-105.
  48. Bateman E.D., Britton M., Carrillo J. et al. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin. Drug. Invest. 1998, v. 16 (3), p. 193-201.
  49. Nelson H.S., Chapman K.R., Pyke S.D. et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol. 2003, v. 112 (1), p. 29-36.
  50. Angus R., Reagon R., Cheesbrough A. Short-acting beta2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent blecomethasone and long-acting beta2-agonist or salmetero/fluticasone propionate combination. Int. J. Clin. Pract. 2005, v. 59 (2), p. 156-162.
  51. Marceau C., Lemiere C., Berbiche D. et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J. Allergy Clin. Immunol. 2006, v. 118 (3), p. 574-581.
  52. Theophilus A., Moore A., Prime D. et al. Co-deposition of salmeterol and fluticasone propionate by a combination inhaler.Int. J. Pharm. 2006, v. 26, p. 313 (1-2), 14-22.
  53. Teply R., Campbell J., Hilleman D.l Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/ Journal of Asthma and Allergy. 2010, v. 3, p. 1-8.
  54. Stoloff S.W., Stempel D.A., Meyer J. et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin.Immunol. 2004, v. 113, p. 245-251.
  55. Boulet L.P. Once-daily inhaled corticosteroids for the treatment of asthma. Curr. Opin. Pulm. Med. 2004 v. 10, p. 15-21.
  56. Derom E. Adherence issues in aerosol therapy. Medical aerosols. Budapest, Hungary November 25-26, 2005. ERS School Courses, 2005.
  57. O'Connor R.D., Patrick D.L., Parasuraman B. et al. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/ salmeterol dry powder inhaler in patients with asthma. J. Asthma. 2010, v. 47 (2), p. 217-223.
  58. Baptist A.P., Reddy R.C.Inhaled corticosteroids for asthma: are they all the same? J. Clin. Pharm. Ther. 2009, v. 34 (1), p. 1-12. Review.
  59. Byron P.R., Hindle M., Lange C.F. et al. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols. J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23 Suppl 2, p. 59-69.
  60. Lavorini F., Levy M.L., Corrigan C., Crompton G. ADMIT Working Group.The ADMIT series - issues in inhalation therapy. 6) Training tools for inhalation devices. Prim. Care. Respir. J. 2010, v. 19 (4), p. 335-341.
  61. Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines*American College of Chest Physicians/American College of Asthma, Allergy, and Immunology CHEST January. 2005, v. 127, No. 1, p. 335-371.
  62. Dolovich M.B., Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2010, Oct 29.
  63. Smith I.J., Bell J., Bowman N. et al. Inhaler devices: what remains to be done? J. Aerosol. Med. Pulm. Drug. Deliv. 2010, v. 23 Suppl 2, p. 25-37.
  64. Демко И.В., Толкушин А.Г., Козлов С.Н., Чучалин А.Г. Фармакоэкономический анализ использования поддерживающего противоастматического лечения. Пульмонология. 2008, № 4, c. 67-72.
  65. McKeage K., Keam S.J. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2009, v. 69 (13), p. 1799-828.
  66. Shepherd J., Rogers G., Anderson R. et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess. 2008, v. 12 (19), iii-iv, p. 1-360.
  67. Ягудина Р.И., Куликов А.Ю., Огородова Л.М. и соавт. Оптимизация поддерживающей терапии с использованием фармакоэкономической модели бронхиальной астмы (ОПТИМА). Сравнительный анализ фиксированных комбинаций ингаляционных глюкокортикостероидов и длительно-действующих бета-агонистов на примере Томской области. Фармакоэкономика. 2010, № 1, c. 40-46.
  68. Fritscher L., Chapman K.R. Seretide: a pharmacoeconomic analysis. J. Med. Econ. 2008, v. 11 (3), p. 555-570.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2011



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies